Central Message
Understanding molecular mechanisms of COVID-19 disease is crucial for cardiothoracic surgeons.
See Article on page e217.
The global pandemic of coronavirus disease 2019 (COVID-19) has major implications for cardiothoracic surgeons. It has influenced all aspects of our lives. Resources that previously seemed unlimited have become scarce. The COVID-19 pandemic has not only resulted in dramatically increased need for urgent mechanical cardiorespiratory support in the epicentres of disease outbreaks but also put significant pressure on perioperative management of patients—ranging from congenital heart disease to organ transplantation—everywhere in the world. Thus, the importance of mechanistic understanding of the molecular and cellular pathophysiology of COVID-19 disease cannot be overemphasized. In this context, Thankam and Agrawal
1
explored the mechanistic basis of COVID-19 disease. Their comprehensive review focuses on the interaction between COVID-19 infection, cardiovascular disease, and the angiotensin signaling pathway. Coronavirus binds to the angiotensin converting enzyme (ACE) 2 molecule and enters cells where it triggers a series of signaling pathways (Figure 1). Decrease in ACE2, an enzyme with its own anti-inflammatory effect, appears to unbalance the angiotensin system. Excessive angiotensin pathway stimulation increases vascular permeability and as such, contributes to mononuclear cell and neutrophil extravasation as well as generalized endotheliitis.2
The frequently used cardiovascular drugs, ACE inhibitors, and angiotensin receptor blockers interact in the angiotensin pathway, but their effect, if any, on disease progression remains unclear. A cytokine storm caused by viral infection in susceptible patients results in rapid disease progression from mild or moderate to severe.Among the most intriguing aspects of COVID-19's viral interaction with the immune system is an exceptionally low rate of severe disease in children, a seemingly most-vulnerable population. Emerging evidence suggests this may be related to important differences in immune response in children compared with adults, in particular in the circulating levels of T-regulatory cells and interleukin-17 producing T-helper cells.
3
Despite the paucity of severe respiratory disease in the vast majority of children, an outbreak of severe Kawasaki-like disease in children has been reported from the Italian epicenter of COVID-19 infection.4
Thus, generalized virus-induced endotheliitis combined with immature immune response in children may result in similar outbreaks of Kawasaki-like disease in the countries influenced by COVID-19 epidemics.4
The role of extracorporeal life support (ECLS) in patients with severe adult respiratory distress syndrome was established following a landmark randomized controlled trial and reinforced through experience in supporting patients with adult respiratory distress syndrome in the influenza pandemic of 2009.
5
,- Peek G.J.
- Mugford M.
- Tiruvoipati R.
- Wilson A.
- Allen E.
- Thalanany M.M.
- et al.
Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial.
Lancet. 2009; 374: 1351-1363
6
Early reports of ECLS for patients with COVID-19 demonstrate 30% to 50% mortality rates and prolonged duration of support, with many patients still remaining on ECLS at the time of publication.7
,8
The Extracoporeal Life Support Organization has provided guidance on the use of ECLS to support COVID-19 patients.9
Heart and lung transplantation in context of a global pandemic poses a special set of challenges due to the substantial resource consumption and the additive risk of COVID-19 infection to immunosuppressed patients. The International Society of Heart and Lung Transplantation suggests that heart and lung transplantation services should focus on those patients in most urgent need to fulfill our obligation to provide transplant to candidates while maintaining capacity for COVID-19 patients.
10
As expected, the initial reports of COVID-19 infection in solid organ transplantation recipients demonstrated higher mortality rates compared with the general population,- Holm A.M.
- Mehra M.R.
- Courtwright A.
- Teutebrg M.D.
- Sweet S.
- Potena L.
- et al.
Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 task force statement.
J Heart Lung Trans. April 25, 2020; ([Epub ahead of print])
11
an important consideration for patients awaiting transplantation.The late sequelae of COVID-19 infection are not yet fully appreciated. The acute cytokine storm and endotheliitis seen at the time of infection may result in accelerated cardiovascular disease. For instance, outbreaks of Kawasaki-like disease may cause coronary aneurysm, which necessitates coronary artery bypass in childhood. Time will tell. The COVID-19 pandemic is not over. A thorough understanding of the mechanism of COVID-19 will make us prepared for whatever comes.
References
- Molecular chronicles of cytokine burst in patients with coronavirus disease 2019 (COVID-19) with cardiovascular diseases.J Thorac Cardiovasc Surg. 2021; 161: e217-e226
- Endothelial cell infection and endotheliitis in COVID-19.Lancet. 2020; 395: 1417-1418
- IL-6: regulator of Treg/Th17 balance.Eur J Immunol. 2010; 40: 1830-1835
- An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.Lancet. 2020; 395: 1771-1778
- Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial.Lancet. 2009; 374: 1351-1363
- Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome.JAMA. 2009; 302: 1888-1895
- Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in COVID-19: experience with 32 patients.ASAIO J. 2020; 66: 722-730
- Extracorporeal membrane oxygenation for coronavirus disease 2019 in Shanghai, China.ASAIO J. 2020; 66: 475-481
- Initial ELSO guidance document: ECMO for COVID-19 patients with severe cardiopulmonary failure.ASAIO J. 2020; 66: 472-474
- Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 task force statement.J Heart Lung Trans. April 25, 2020; ([Epub ahead of print])
- COVID-19 in solid organ transplant recipients: initial report from the US epicenter.Am J Transplant. 2020; 20: 1800-1808
Article info
Publication history
Published online: June 06, 2020
Accepted:
May 28,
2020
Received in revised form:
May 28,
2020
Received:
May 28,
2020
Footnotes
Disclosures: The authors reported no conflicts of interest.
The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.
Identification
Copyright
Crown Copyright © 2020 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery
User license
Elsevier user license | How you can reuse
Elsevier's open access license policy
Elsevier user license
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy
ScienceDirect
Access this article on ScienceDirectLinked Article
- Molecular chronicles of cytokine burst in patients with coronavirus disease 2019 (COVID-19) with cardiovascular diseasesThe Journal of Thoracic and Cardiovascular SurgeryVol. 161Issue 2
- PreviewThe emergence and pandemic spread of an acute respiratory disease caused due to a novel strain of SARS-Cov-2 (severe acute respiratory syndrome coronavirus 2), COVID-19 (coronavirus disease 2019) continues to threaten the global population. The increased rate of COVID-19 infection has resulted in a global health crisis and caused a huge economic burden in affected nations across the globe. The virus is believed to originate in bats and transmitted to humans possibly through an unknown carrier species in Wuhan, Hubei province, China, sometime in December 2019.
- Full-Text
- Preview